Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 539Neoplasms 482Carcinoma, Non-Small-Cell Lung 395Prostatic Neoplasms 314Colorectal Neoplasms 300Lung Neoplasms 265Neoplasm Metastasis 222Ovarian Neoplasms 199Leukemia, Myeloid, Acute 197Pancreatic Neoplasms 187Multiple Myeloma 174Recurrence 135Squamous Cell Carcinoma of Head and Neck 133Stomach Neoplasms 131Brain Neoplasms 131Melanoma 127Carcinoma, Hepatocellular 126Glioblastoma 121Endometrial Neoplasms 121Triple Negative Breast Neoplasms 113Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Hematologic Neoplasms 104Head and Neck Neoplasms 100Carcinoma, Renal Cell 98Lymphoma 96Urinary Bladder Neoplasms 93Sarcoma 91Glioma 88Rectal Neoplasms 83Small Cell Lung Carcinoma 82

Interventions

pirtobrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Chromosome 17 deletion × 90 days × Clear all
NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc

Phase 3 Recruiting
306 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡